#Cancer Treatment #Denmark #Copenhagen #Adcendo #ADCs

Adcendo ApS to Join Upcoming September Investor Conferences

Adcendo ApS, a forward-thinking clinical-stage biotechnology firm based in Copenhagen, Denmark, has announced its participation in a series of important investor conferences scheduled for September. These events present an opportunity for the firm to showcase its cutting-edge work in developing first-in-class antibody-drug conjugates (ADCs) for treating cancers with significant unmet medical needs.

The September schedule includes participation in five key conferences:

1. Citi 2025 Biopharma Back-to-School Conference
- Format: One-on-one meetings
- Date: Tuesday, September 2, 2025
- Location: Boston, MA

2. Wells Fargo 2025 Healthcare Conference
- Format: Company presentation
- Date: Wednesday, September 3, 2025
- Time: 3:45 PM ET
- Location: Boston, MA

3. Cantor Global Healthcare Conference
- Format: One-on-one meetings
- Date: Thursday, September 4, 2025
- Location: New York, NY

4. Morgan Stanley 23rd Annual Global Healthcare Conference
- Format: Company presentation
- Date: Monday, September 8, 2025
- Time: 1:50 PM ET
- Location: New York, NY

5. Bank of America Healthcare Trailblazers Private Company Conference
- Format: One-on-one meetings
- Date: Wednesday, September 17, 2025
- Location: Boston, MA

These conferences are valuable platforms for Adcendo to connect with investors, share insights, and highlight their innovative approach to oncology. With a robust pipeline focused on ADCs, the company aims to address significant challenges in cancer treatments, particularly in areas where current therapies fall short.

About Adcendo ApS

Founded in Denmark, Adcendo is on the cutting edge of biopharmaceutical innovation, dedicated to tackling cancers that have high unmet medical needs. The company's strategy focuses on developing novel ADCs that integrate optimized linker-payload combinations and unique target selections, ensuring a more effective approach to combating various cancer types.

Under the leadership of a seasoned team experienced in advancing ADCs through regulatory approval, Adcendo continues to push the boundaries of cancer therapy. The firm is situated in Copenhagen, with operational ties in Boston, positioning it strategically within a global health care ecosystem.

As the company prepares for the upcoming investor conferences, it invites interested parties to learn more about its initiatives and commitment to oncology innovation. Further information can be obtained via their official website, adcendo.com, or through their LinkedIn page.

With these engagements unfolding in September, Adcendo stands poised to reinforce its presence among key players in the biotech field, fostering a deeper understanding of its mission and the critical advancements in cancer treatment it is pioneering.